These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

362 related articles for article (PubMed ID: 30858217)

  • 41. In vitro activity of dalbavancin and five comparator agents against common and uncommon Gram-positive organisms isolated from cancer patients.
    Rolston KV; Wang W; Nesher L; Shelburne SA; Prince RA
    J Antibiot (Tokyo); 2016 May; 69(5):381-7. PubMed ID: 26626876
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Dalbavancin in Gram-positive periprosthetic joint infections.
    Simon S; Frank BJH; Hartmann S; Hinterhuber L; Reitsamer M; Aichmair A; Dominkus M; Söderquist B; Hofstaetter JG
    J Antimicrob Chemother; 2022 Jul; 77(8):2274-2277. PubMed ID: 35678452
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Dalbavancin, a long-acting lipoglycopeptide for the treatment of multidrug-resistant Gram-positive bacteria.
    Decousser JW; Bourgeois-Nicolaos N; Doucet-Populaire F
    Expert Rev Anti Infect Ther; 2007 Aug; 5(4):557-71. PubMed ID: 17678421
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A Reference Broth Microdilution Method for Dalbavancin In Vitro Susceptibility Testing of Bacteria that Grow Aerobically.
    Koeth LM; DiFranco-Fisher JM; McCurdy S
    J Vis Exp; 2015 Sep; (103):. PubMed ID: 26381422
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Analysis of dalbavancin in animal models].
    Murillo Ó; El-Haj C
    Enferm Infecc Microbiol Clin; 2017 Jan; 35 Suppl 1():28-32. PubMed ID: 28129818
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Antimicrobial spectrum of dalbavancin. Mechanism of action and in vitro activity against Gram-positive microorganisms].
    Cercenado E
    Enferm Infecc Microbiol Clin; 2017 Jan; 35 Suppl 1():9-14. PubMed ID: 28129822
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Dalbavancin as salvage therapy in difficult-to-treat patients for diabetes-related foot osteomyelitis.
    Boucher A; Pradier M; Lafondesmurs B; Thill P; Patoz P; Blondiaux N; Joulie D; Hennart B; Robineau O; Senneville E
    Infect Dis Now; 2024 Feb; 54(1):104835. PubMed ID: 37972818
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A Narrative Review on the Role of Dalbavancin in the Treatment of Bone and Joint Infections.
    Dimopoulou D; Mantadakis E; Koutserimpas C; Samonis G
    Antibiotics (Basel); 2023 Sep; 12(10):. PubMed ID: 37887193
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A comparative review of the lipoglycopeptides: oritavancin, dalbavancin, and telavancin.
    Guskey MT; Tsuji BT
    Pharmacotherapy; 2010 Jan; 30(1):80-94. PubMed ID: 20030476
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections.
    Jauregui LE; Babazadeh S; Seltzer E; Goldberg L; Krievins D; Frederick M; Krause D; Satilovs I; Endzinas Z; Breaux J; O'Riordan W
    Clin Infect Dis; 2005 Nov; 41(10):1407-15. PubMed ID: 16231250
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Emerging resistance in Staphylococcus epidermidis during dalbavancin exposure: a case report and in vitro analysis of isolates from prosthetic joint infections.
    Al Janabi J; Tevell S; Sieber RN; Stegger M; Söderquist B
    J Antimicrob Chemother; 2023 Mar; 78(3):669-677. PubMed ID: 36611258
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Dalbavancin: a review.
    Scheinfeld N
    Drugs Today (Barc); 2007 May; 43(5):305-16. PubMed ID: 17724497
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Safety of Dalbavancin in the Treatment of Skin and Skin Structure Infections: A Pooled Analysis of Randomized, Comparative Studies.
    Dunne MW; Talbot GH; Boucher HW; Wilcox M; Puttagunta S
    Drug Saf; 2016 Feb; 39(2):147-57. PubMed ID: 26715497
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Dalbavancin activity against selected populations of antimicrobial-resistant Gram-positive pathogens.
    Streit JM; Sader HS; Fritsche TR; Jones RN
    Diagn Microbiol Infect Dis; 2005 Dec; 53(4):307-10. PubMed ID: 15922534
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Antimicrobial activity of dalbavancin tested against Gram-positive clinical isolates from Latin American medical centres.
    Gales AC; Sader HS; Jones RN
    Clin Microbiol Infect; 2005 Feb; 11(2):95-100. PubMed ID: 15679482
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Off-label use of dalbavancin in children: a case series.
    Gamell A; Velasco-Arnaiz E; López-Ramos MG; Ríos-Barnés M; Simó-Nebot S; Fumadó V; Noguera-Julián A; Fortuny C
    J Antimicrob Chemother; 2024 Aug; 79(8):2062-2067. PubMed ID: 38958260
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Can dalbavancin be used as a catheter lock solution?
    Díaz-Ruíz C; Alonso B; Cercenado E; Cruces R; Bouza E; Muñoz P; Guembe M
    J Med Microbiol; 2018 Jul; 67(7):936-944. PubMed ID: 29771236
    [No Abstract]   [Full Text] [Related]  

  • 58. Dalbavancin for infective endocarditis: a single centre experience.
    Durante-Mangoni E; Boccia F; Ursi MP; Karruli A; Andini R; Galdo M; Zampino R
    J Chemother; 2021 Jul; 33(4):256-262. PubMed ID: 33073724
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Dalbavancin (BI-387) for the treatment of complicated skin and skin structure infection.
    Leuthner KD; Yuen A; Mao Y; Rahbar A
    Expert Rev Anti Infect Ther; 2015 Feb; 13(2):149-59. PubMed ID: 25578881
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effective use of a two-dose regimen of dalbavancin to treat prosthetic joint infections and spinal hardware infections.
    Doub JB; Alkayali T; Amoroso A; Nandi S; Talwani R
    Eur J Orthop Surg Traumatol; 2023 Dec; 33(8):3655-3659. PubMed ID: 37270761
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.